北京安韦拓生物医药

Anveto Biopharma is a Beijing-based biotechnology company specializing in the development of next-generation Adeno-Associated Virus (AAV) gene therapies. Founded in 2021, the company focuses on addressing unmet medical needs in ophthalmology and rare genetic disorders through its proprietary AAV vector engineering platform. Its lead program, AVT-001, is an investigational gene therapy for wet age-related macular degeneration (nAMD) that has advanced into clinical trials. The company's pipeline also includes preclinical programs for Hemophilia B and Pompe disease. Anveto has secured significant backing from prominent venture capital firms to accelerate its research and manufacturing capabilities.